Great. updates thanks, and to of on these always for saved this In It's for our fall. get joining. all Thanks, Steph, we truth, calls. fund a pleasure everybody,
So meaningful updates, today other I'm is a talking couple happy couple to execution about. things and clinical of of that be of a a but points relatively straightforward set really
So with reminder. just Slide quickly thank a the in you again.
I'll X start deck on
is kind and are Just we year, is this growth where year a of expansion which of us. for this
as as very coming So the soon franchise, our next, franchise, as where data the on the over much we're that's months. across -- focused future anti-FcRn data call meaningful we clinical delivering multiple well as sets of it, have X near some
shortly, have coming beyond on.
We're sarcoidosis to. our a III in where very in We'll beginning brepocitinib, looking PsO the be lot focus for continued we and at bit Phase clinical then VTAMA including data is over our forward development really NIU in work continue story much we'll the to pipeline, activity. about looking and We certainly today, in that acceleration and little namilumab so AD on pipeline, some programs. but year label our have hard talk in program be I of we this are of time. a that of expansion And there's with at ], mid-late-stage the [ volumes for VTAMA revenues expanding know where
unveiling will of there. so month, far work to then capital on on continuing continue for next more hold so program shares much few on. undisclosed just be a to We around And we aggressively allocation, so and prioritizing discussed use the our weeks buy back to thinking capital
all of stands. months, ] without talk the proud at sometimes super pipelines time so we'll one still where then about pipeline of sure of there, on in it currently we -- we of brepocitinib have next, in I'm are lot a call you as these We get particular, the Slide both the about the opportunities pipeline, And about IMVT, ], I questions data excited have it, the [indiscernible] excited XX [ coming one things that our about X shortly. look FDF IMVT [ more every best breadth the and pivotal but today
III few begin our program. XX-week planning next FDA completed opportunity on to And of top NIU line weeks enrollment we've end in Slide on study ever subjects confidence meeting largest data X. is are with it sites, in XX enrollment year, is Phase can the across we've in a we completed the main that and of a in with One the Phase II now back. study for DM starting XXX III future our that study the Phase say And It's expect updates brepocitinib, the III NIU completed quarter, interventional second dermatomyositis. is on near now half study we So the which in conducted. Phase
the the may can and so MG recall, had study schedule, bit At that, now original that, we has the for probably quarter programs, next completed we'll quarter as in say next you data initiation little first And program only talk for as study. minute. discussed. track the in we'll on behind of enrollment, well slight MG for We about in registrational a year of last get as year, previously multiple a Immunovant, announced a that that we remain as delay other more we've
or Phase It September in upcoming I to will one. our of that. be this the unveil said, we will as likely the hub like will do do month, a excited presentation We II some next data, combination home program,
going X. say So that got Slide approval have the the of July, definition in and other the may will they've a you September at to that XXXX. that approved, continue then and get many begun. we achieved we're couple could IP to Japanese litigation One milestone some Moderna milestone. a we of progress resulted million now, looking be around milestones forward the getting together just our to million clinical in making with coming trial that time.
And schedule from we so received Genevant so seen door. to more we then continues updates year a Roche just information of for is remaining vaccines $XX the of some $XXX case proceeds in a in Telavant be we slightly about We're on at from pleased for to They important cash And if that regulatory get we VTAMA, beginning our in of the portion requested have now related discovery COVID of which, that hit
So that been this received has month.
multiple we even invested milestone program. million the So this capital in originally pleased with that. still even that $XXX And of the in obviously, a though
updates the quarter. for are main those the So
of on in minutes some things particular. I a to want spend couple
review it fact, a view our the where say, for B-cell is are beyond is Immunovant as biology me, I'd last opportunity. pie. we few a field, into a I conversations conversation a around months, some -- them One over level think our I the of apportionment that just FcRn, drawn have been to having the of and of biology to very enthusiasm we've been We've that One and broad. about of and only bit occurs for anti-FcRn immunology in but around little small regret the
So breadth I supports the excited where that highlight, just the been just are, so opportunity and reminder that's of why the we think generated little we program. of here of amount again, of we wanted to are a data about the a bit
than look, do best-in-class said That to as without any on our albumin in that view, comes, from impacts really LDL, in IgG of deeper a that deeply multiple We suppress obviously, potentially reminder, things which like places. XX, profile So ability we've and has or on antibodies any believe first as IMVT-XXXX other was a our foremost, first and something Slide the program. this obviously generation anti-FcRn our affected here.
be think an potentially And likelihood worth will that of to auto-injector, field we be and all versus where compelling is for patients with a it to will now, relative where we injection really years. field think sense IMVT-XXXX enable our where being a in be simple I a format the -- then subject that the are remembering and also couple FDA will right it's launch home, certainly And should self-administration in that. to subcutaneous in differentiated is to going even able differentiated option a okay be at
some X with of current what couple there and years of million, just indications has over as the There back are Slide and is on addressable XXX,XXX of anti-FcRn total it demonstrated. been past explosive to number relatively addressable to with total patients. eight for well. population in has and to antibodies growth the now add XX absolutely FcRn near breadth FcRn a XX, development development growing were the There in often indications expect in Relying that future XXXX, we about
now So late-stage indications, antibodies us, a that population of amount X in been which this [indiscernible]. by about have studied unmet at data can in a Batoclimab moment biology in about Graves mechanism, of patient see Slide X generated Batoclimab you patients. of its this there different some huge X,XXX area just across need.
On positive tremendous anti-FcRn XX There's to XX, and prior studies kind a of and have been
Some efficacy that compelling well-tolerated a wide as of generated in pretty point a such just But a really overall, meaningful benefit of this class recently. diseases. others clinical was at in by and range shows children picture
about So that. excited we're really
than The XX, is autoimmune to don't that Slide earlier this this -- us want IgG slide been of there's would degradation I enthusiastic the these time And I on about going disease. so there's it's this piece engagers great really but to We the been suggest on still interest, cleared sense it's much meant that to lot biology. not for do much other on spend it's let's or some elegantly of of biology, say of biology. is mechanisms. CAR-T think FcRn too competitive I T-cell But a lot to much mechanisms, other in that we think is a or in only interesting B-cell nothing are are to some bar work in of FcRn. say,
immunology, see thousands again, for positive can here, in our You studies, II positive Phase multiple patients. multiple approvals of multiple in class III Phase studies
validation in and picture opportunity. up of of the terms a sets level the just It proximity of different the
we that these excited think so are other make in interesting, the our other place of field. about competitive classes we're areas. vis-a-vis we closely, many them And Again, what in watching investments
But we're positioned we watching of looks is And really terms areas. wants imagine can you stage of and biology. feel Slide biggest the so to in good about how these compare drugs. XX, everyone competitively to FcRn the themselves we just like different it where And opportunity.
On
studied in larger of is liked maybe history, where versus at time this have and you to things stack FcRns was here. in feels be various were and about at much growing. sold it And the exciting it at liked We on overdone, the than try TNF are basis. is if the stage the a a couple so I of indications I but things points biology, just extremely comparison a Humira is But FcRn well in being right? time-adjusted the where it up one of set class about TNF of
launch, novel just class able their biology, to by own, being TNF yet with being call foundational phenomenal a after TNFs achieve many their of other XX years TNFs $X.X -- competing approved that. FcRn in time, there class approved of of competitive class is down obviously, were chance sales build, we're And there's didn't TNF portion meaningful first being a forecast, I on tolerated, billion in the the our look at about street forecasts, over able.
And of point, launch. think class think meaningfully especially was the will its the at a net you I it's notable development, that first you breadth reported given year early post directly if from these, there sort were X in quicker results well indications The and MOAs look really
opportunity we our spaces, not other So is there's at I couldn't as very we and think is It's these I look take, indications these view as Notably, large -- are look indications. think the -- these here but are of many examples other many Many at big. just indications. broad. we
we've of Slide the accommodate TNF so an that of And XX indications program handful that mechanisms. a success big And given multiple enough, got can are indications in impact. to any a tent.
On programs, for many them even big is multiple plan. big aggressive This a has make as
plan. registrational by fiscal up X XXXX to potential next moving that in will fiscal about excited indications are year, X be year. XX this to programs We
Really end the So excited to by the we're with X to going data IND approach. expected of generate year. in of for this what active to validate we're is months coming what that doing calendar XXXX, be
revisit and you things. don't I'll on but topic. Immunovant, smaller that why couple say other of A So
it looks year-over-year quick quarter-on-quarter Slide revenue are frequently are get that. million They're the on flattish. growing every XX% up year. One quarter, to volumes doing we last single-digit a flat, volumes relatively we flat continue for yield. the well to same question, product on quarter, script see Script update it the relative VTAMA percent looks quarter on for and just GTN XX, in Notably, actually -- relatively $XX.X
the build and over suggests for slowly novel we're to volume the to So psoriasis we perspective, happy the we with best the willingness that suggests change, remain it continuing topical. -- that that, and market, from into are selling behavior this time
main all think before this AD up will we that psoriasis as the the in the in is us I approval at which end after and said come sets for, well launch really of year. event, that
a year because quickly not have had positive volume payer that of GTN the are sort this think that the rebate say, were we on I we we yield now. reset I'll fluctuations overall here. in on a trend had earlier GTN just contract getting obscured effectively year one that rebating last
in overall expect and difference some level. Notably this sort [indiscernible] have will outside build my reset to I increase expectations, So like but term, from of higher instead here. one that it here, been a think from I continues an time it of continue of a of to that onetime don't year, accrete also to very might will over GTN. bolt-on Long be hope we from just net I here in contract. have price huge resulted
to everything we direction see wanted So in continue to. that trending the we
The key catalysts on upcoming Slide XX.
Namilumab, data we're We trial First again, of had mean. external think in the data of excited -- that to there. presenting XXXX September. be Phase top from plan the positive, have sort going coming excited area line some development if about in really will on we're we'll opportunity. out not putting Graves' Also But well data undisclosed now. out data batoclimab that sarcoidosis, this that great here, of detailed as data we're they we are upcoming in study this to focus exciting not put II we've fall, right information is all, positive what if from slide, are but Graves' pretty clinical -- program, an this got as a
in And the study VTAMA, expansion, the Phase X this X end then year, the from together in we label data as we, programs all myasthenia year, fiscal event, the to the with more the near talked by of in hopefully in about end gravis, CIDP. IIb future. registrational at initiating well big of atopic batoclimab of year speaking from as coming XXXX, of and dermatitis by X end Immunovant which potential as fiscal then the period the about of data again, the
of we equivalents We quick shares just sort our done of overall, to of quarter So net had up cash normal that quarter. relatively revenues think in the income you to [ $X.X and $XX financial Expenses I of within and update this $XX that year this come that then update, for balance. value billion in a perspective. ended of about million, cash a We actually reflects carrying say, XX, with historical a finally, pretty us want Sumitomo revenues made million. Net last had this before April, And from product repurchase including the about quarter we $XX slide debt Slide ]. has quarter outstanding as wrap on bit, down of the million. I had the on I a thanks XXX sort million well, our Dermavant renegotiation have at can the see finance
this So wrap the Slide with XX. on presentation I'll portion of that, up
BD ahead coming months. I rich a You catalyst frankly, batoclimab of in exciting can see months the the up pretty that calendar pretty unveil a have coming new generally on with, couple of from to program. work the data between coming side we the and continue
what about see together getting to sure and the times to in to months forward those I'm to multiple continue updates developed. next few talk this looking all really So will be
I that, it Q&A. will Thank presentation for the and back with you listening, I'll morning. the again the And for up operator for hand to wrap
